Evidence for age and sex differences in the secondary prevention of stroke in Scottish primary care

Stroke

Volumn 36, Issue 8, 2005, Pages 1771-1775

  Simpson, C R ^a   Wilson, C ^b   Hannaford, P C ^a   Williams, D ^b  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b NHS GRAMPIAN   (United Kingdom)

Author keywords

Age; Anticoagulation; Antihypertensive agents; Antiplatelet drugs; Database; Epidemiology; Prevention; Sex; Stroke management

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; THIAZIDE DIURETIC AGENT; WARFARIN;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; COMORBIDITY; DIABETES MELLITUS; FEMALE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PERIPHERAL VASCULAR DISEASE; PRESCRIPTION; PREVALENCE; PRIMARY HEALTH CARE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SECONDARY PREVENTION; SEX RATIO; STATISTICAL ANALYSIS; STROKE; UNITED KINGDOM;

AGE FACTORS; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTICOAGULANTS; ANTIHYPERTENSIVE AGENTS; CEREBROVASCULAR ACCIDENT; FEMALE; HUMANS; ISCHEMIA; LOGISTIC MODELS; MALE; MIDDLE AGED; ODDS RATIO; PLATELET AGGREGATION INHIBITORS; PRIMARY HEALTH CARE; RETROSPECTIVE STUDIES; SCOTLAND; SEX FACTORS; WARFARIN;

EID: 23244448811     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.0000173398.99163.9e     Document Type: Article

References (24)

1. Sans S, Kesteloot H, Kromhout D. The burden of cardiovascular diseases mortality in Europe. Task Force of the European Society of Cardiology on Cardiovascular Mortality and Morbidity Statistics in Europe. Eur Heart J. 1997;18:1231-1248.
2. The Scottish Executive Department of Health. Coronary Heart Disease and Stroke: Strategy for Scotland. Edinburgh: The Scottish Executive: 2002.
3. Rodgers A, MacMahon S, Gamble G, Slattery J, Sandercock P, Warlow C. Blood pressure and risk of stroke in patients with cerebrovascular disease. The United Kingdom Transient Ischaemic Attack Collaborative Group. BMJ. 1996;313:147.
4. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6.105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001; 358:1033-1041.
5. Intercollegiate Stroke Working Party National Clinical Guidelines for Stroke, 2nd ed. London: The Royal College of Physicians; 2004.
6. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy-1: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. BMJ. 1994;308: 81-106.
7. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvaslalin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7-22.
8. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of amithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med. 1994;154: 1449-1457.
9. Hippisley-Cox J, Pringle M, Crown N, Meal A, Wynn A. Sex inequalities in ischaemic heart disease in general practice: cross sectional survey. BMJ. 2001;322:832.
10. Simpson CR, Hannaford P, Williams D. Evidence for inequalities in the management of coronary heart disease in Scotland. Heart. 2005;91: 630-634.
11. Holroyd-Leduc JM, Kapral MK, Austin PC, Tu JV. Sex differences and similarities in the management and outcome of stroke patients. Stroke. 2000;31:1833-1837.
12. Glader EL, Stegmayr B, Norrving B, Terent A, Hulter-Asberg K, Wester PO, Asplund K. Riks-Stroke Collaboration. Sex differences in management and outcome after stroke: a Swedish national perspective. Sroke. 2003;34:1970-1975.
13. Di Carlo A, Lamassa M, Baldereschi M, Pracucci G, Basile AM, Wolfe CD, Giroud M, Rudd A, Ghetti A, Inzitari D. European BIOMED Study of Stroke Care Group. Sex differences in the clinical presentation, resource use, and 3-month outcome of acute stroke in Europe: data from a multicenter multinational hospital-based registry. Stroke. 2003;34: 1114-1119.
14. Kapral MK, Wang H, Mamdani M, Tu JV. Effect of socioeconomic status on treatment and mortality after stroke. Stroke. 2002;33:268-273.
15. de Koning JS, Klazinga N, Koudstaal PJ, Prins A, Borsboom GJ, Peeters A, Mackenbach JP. Deprivation and systematic stroke prevention in general practice: an audit among general practitioners in the Rotterdam region. The Netherlands. Eur J Public Health. 2003;13:340-346.
16. Milne RM, Taylor MW, Taylor RJ. Audit of populations in general practice: the creation of a national resource for the study of morbidity in Scottish general practice. J. Epidemiol Community Health. 1998;52(Suppl 1):20S-24S.
17. Whitelaw FG, Nevin SL, Milne RM, Taylor RJ, Taylor MW, Watt AH. Completeness and accuracy of morbidity and repeat prescribing records held on general practice computers in Scotland. Br J Gen Pract. 1996; 46:181-186.
18. Information and Statistics Division. CMR Data Quality Assurance Report. Edinburgh: NHS Scotland: 2002.
19. Carstairs V, Morris R. Deprivation and Health in Scotland. Aberdeen: Aberdeen University Press: 1991.
20. Deplanque D, Leys D, Parnetti L, Schmidt R, Ferro J, De Reuck J, Mas JL, Gallai V. SAFE II Investigators. Stroke prevention and atrial fibrillation: reasons leading to an inappropriate management. Main results of the SAFE II study. Br J Clin Pharmacol. 2004;57:798-806
21. Wenger NK, Speroff L, Packard B. Cardiovascular health and disease in women. N Engl J Med. 1993;329:247-256.
22. Shepherd J, Blauw, GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, Ford I, Gaw A, Hyland M, Jukema JW, Kamper AM, Macfarlane PW, Meinders AE, Norrie J, Packard CJ, Perry U, Stott DJ, Sweeney BJ, Twomey C, Westendorp RG, PROSPER study group. PROspective Study of Pravastatin in the Elderly at Risk. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002;360:1623-1630.
23. Lipids and the Primary Prevention of Coronary Heart Disease. Edinburgh: Scottish Intercollegiate Guidelines Network: 1999.
24. Hopper S. Pierce M Aspirin after myocardial infarction: the importance of over-the-counter use. Fam Pract. 1998;15(Suppl 1):S10-S13.